Anesiva's media center is designed to provide reporters with easy access to news about the company and its products for stories in development. If you don't find what you are looking for or need more information, please contact us.
| All Releases |
|---|
 |
Corgentech Appoints Nancy Donahue Vice President of Cardiovascular Marketing
Mar 23, 2004
|
55.8 KB
|
| |
(SOUTH SAN FRANCISCO, Calif., March 23, 2004) -- Corgentech Inc. (Nasdaq: CGTK), a biotechnology company, announced today that Nancy Donahue has been appointed vice president of cardiovascular marketing. Previously, Ms Donahue worked for 15 years in sales and marketing for GlaxoSmithKline, where she spent nearly half of her tenure mark...
|
|
|
Corgentech Announces Its Initial Public Offering
Feb 12, 2004
|
46.7 KB
|
| |
(SOUTH SAN FRANCISCO, Calif., February 12, 2004) -- Corgentech Inc. announced today the pricing of its initial public offering of 6,000,000 shares of its common stock at a price to the public of $16 per share. All of the shares are being offered by Corgentech. Corgentech has granted the underwriters a 30-day option to purchase up to an additional 9...
|
|
|
Corgentech Files Registration Statement for Initial Public Offering
Dec 4, 2003
|
46.3 KB
|
| |
(SOUTH SAN FRANCISCO, Calif., December 4, 2003) -- Corgentech Inc. announced today that it has filed a registration statement on Form S-1 with the Securities and Exchange Commission for an initial public offering of shares of its common stock.
The underwriters of the offering will be Credit Suisse First Boston and Lehman Brothers, acti...
|
|
|
Bristol-Myers Squibb and Corgentech Enter Global Agreement to Develop and Commercialize Novel Cardiovascular Therapy
Oct 13, 2003
|
73.2 KB
|
| |
(SOUTH SAN FRANCISCO, Calif. and NEW YORK, NY, October 13, 2003) -- Bristol-Myers Squibb Company (NYSE: BMY) and Corgentech Inc., a privately held biotechnology company, today announced they have entered into an agreement to jointly develop and commercialize Corgentech's E2F Decoy (edifoligide sodium), a first-of-its-kind E2F Decoy trea...
|
|
|
Corgentech Completes Enrollment of Pivotal Phase 3 Trial Studying E2F Decoy, a Novel Vascular Therapy
Oct 1, 2003
|
54.8 KB
|
| |
SOUTH SAN FRANCISCO, Calif., Oct. 1, 2003 -- Corgentech Inc., a privately held biotechnology company, announced today that the company has completed patient enrollment in a second pivotal Phase 3 clinical trial to evaluate its lead product, CGT003, a first-of-its-kind E2F Decoy treatment for the prevention of graft failure following perip...
|
|
|
Click here to download our most recent fact sheet.